26 related articles for article (PubMed ID: 28737025)
1. Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia.
Almirall J; Bolíbar I; Serra-Prat M; Palomera E; Roig J; Hospital I; Carandell E; Agustí M; Ayuso P; Estela A; Torres A;
PLoS One; 2013; 8(9):e73271. PubMed ID: 24039899
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults.
Polsky D; Bonafede M; Suaya JA
BMC Health Serv Res; 2012 Oct; 12():379. PubMed ID: 23113880
[TBL] [Abstract][Full Text] [Related]
3. Evidence supports the use of hydrocortisone for patients with community-acquired pneumonia.
Lu DE; Chang CY; Cheng SW; Kang E; Lee CH; Chen KH
Crit Care; 2024 Feb; 28(1):55. PubMed ID: 38378580
[No Abstract] [Full Text] [Related]
4. Predictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study.
Lüthi-Corridori G; Boesing M; Roth A; Giezendanner S; Leuppi-Taegtmeyer AB; Schuetz P; Leuppi JD
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685667
[TBL] [Abstract][Full Text] [Related]
5. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
Cortoos PJ; Gilissen C; Laekeman G; Peetermans WE; Leenaers H; Vandorpe L; Simoens S
Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
[TBL] [Abstract][Full Text] [Related]
6. [Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio].
Fernández Alvarez R; Gullón Blanco JA; Rubinos Cuadrado G; Jiménez Sosa A; Hernández García C; Medina Gonzálvez A; González Martín I
Arch Bronconeumol; 2001 Oct; 37(9):366-70. PubMed ID: 11674935
[TBL] [Abstract][Full Text] [Related]
7. [Factors associated with prolonged hospital stay in community-acquired pneumonia].
Garcia-Vidal C; Carratalà J; Díaz V; Dorca J; Verdaguer R; Manresa F; Gudiol F
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):160-4. PubMed ID: 19306716
[TBL] [Abstract][Full Text] [Related]
8. CAPECO: Cost evaluation of community acquired pneumonia managed in primary care.
Personne V; Chevalier J; Buffel du Vaure C; Partouche H; Gilberg S; de Pouvourville G
Vaccine; 2016 Apr; 34(19):2275-80. PubMed ID: 26979138
[TBL] [Abstract][Full Text] [Related]
9. Determinants of hospital costs in community-acquired pneumonia.
Reyes S; Martinez R; Vallés JM; Cases E; Menendez R
Eur Respir J; 2008 May; 31(5):1061-7. PubMed ID: 18448502
[TBL] [Abstract][Full Text] [Related]
10. [Influence of initial protocolized treatment with steroids in length of stay and costs of community acquired pneumonia].
Gómez Gómez J; Gómez Torres JL; Hernández Torres A; García Córdoba JA; Canteras Jordana M
Rev Esp Quimioter; 2017 Oct; 30(5):350-354. PubMed ID: 28737025
[TBL] [Abstract][Full Text] [Related]
11. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?
Brown PD
Pharmacoeconomics; 2004; 22(7):413-20. PubMed ID: 15137880
[TBL] [Abstract][Full Text] [Related]
12. [Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area].
Capelastegui A; España PP; Quintana JM; Gorordo I; Martínez Urquiri A; Idoiaga I; Bilbao A
Arch Bronconeumol; 2005 Jun; 41(6):300-6. PubMed ID: 15989886
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
